Zobrazeno 1 - 10
of 160
pro vyhledávání: '"Yutaka Hattori"'
Autor:
Mikio Okayama, Kota Fujimori, Mariko Sato, Koichi Samata, Koki Kurita, Hiromu Sugiyama, Yutaka Suto, Genji Iwasaki, Taketo Yamada, Fumiyuki Kiuchi, Daiju Ichikawa, Maiko Matsushita, Maki Hirao, Hisako Kunieda, Kohei Yamazaki, Yutaka Hattori
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9749-9759 (2023)
Abstract Objective Despite the development of newly developed drugs, most multiple myeloma (MM) patients with high‐risk cytogenetic abnormalities such as t(4;14) or del17p relapse at anin early stage of their clinical course. We previously reported
Externí odkaz:
https://doaj.org/article/37aa41d432754590b8a64747c4ab0f1c
Autor:
Maiko Matsushita, Sho Kashiwazaki, Satoshi Kamiko, Michio Kobori, Makoto Osada, Hisako Kunieda, Maki Hirao, Daiju Ichikawa, Yutaka Hattori
Publikováno v:
Pharmaceuticals, Vol 16, Iss 10, p 1367 (2023)
Several anti-cancer drugs are known to have immunomodulatory effects, including immunogenic cell death (ICD) of cancer cells. ICD is a form of apoptosis which is caused by the release of damage-associated molecular patterns (DAMPs), the uptake of can
Externí odkaz:
https://doaj.org/article/d37f8f3348664981ba1064b1c4af38ba
Autor:
Yutaka Hattori, Shinichiro Okamoto, Ryunosuke Denda, Hisako Kunieda, Hiroki Sugimori, Takahide Kikuchi, Shigemichi Hirose, Kiyoshi Mukai, Yuiko Tsukada, Makoto Osada, Maki Hirao, Kentaro Watanabe, Kohei Yamazaki
Publikováno v:
F1000Research, Vol 11 (2022)
Background: The loss of E-cadherin expression and the induction of N-cadherin are known as hallmarks of the epithelial-to-mesenchymal transition, an essential initial step in the process of metastasis in solid tumors. Although several studies have re
Externí odkaz:
https://doaj.org/article/d78c9be9d14f417485c8266706589daa
Autor:
Yutaka Hattori, Shinichiro Okamoto, Ryunosuke Denda, Hisako Kunieda, Hiroki Sugimori, Takahide Kikuchi, Shigemichi Hirose, Kiyoshi Mukai, Yuiko Tsukada, Makoto Osada, Maki Hirao, Kentaro Watanabe, Kohei Yamazaki
Publikováno v:
F1000Research, Vol 11 (2022)
Background: The loss of E-cadherin expression and the induction of N-cadherin are known as hallmarks of the epithelial-to-mesenchymal transition, an essential initial step in the process of metastasis in solid tumors. Although several studies have re
Externí odkaz:
https://doaj.org/article/cda43e3b8fe244f5a9d4f19b72d33430
Publikováno v:
Vaccines, Vol 8, Iss 4, p 579 (2020)
Despite the availability of therapeutic treatments, multiple myeloma is an incurable haematological disorder. In this study, we aimed to clarify the role of CXorf48 as a therapeutic target in multiple myeloma. Based on a previously identified HLA-A*2
Externí odkaz:
https://doaj.org/article/b41ded786dfb4c2894405d6d96f1ffda
Autor:
Maiko Matsushita, Yohei Otsuka, Naoya Tsutsumida, Chiaki Tanaka, Akane Uchiumi, Koji Ozawa, Takuma Suzuki, Daiju Ichikawa, Hiroyuki Aburatani, Shinichiro Okamoto, Yutaka Kawakami, Yutaka Hattori
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0146371 (2016)
The homeobox protein, PEPP2 (RHOXF2), has been suggested as a cancer/testis (CT) antigen based on its expression pattern. However, the peptide epitope of PEPP2 that is recognized by cytotoxic T cells (CTLs) is unknown. In this study, we revealed that
Externí odkaz:
https://doaj.org/article/2e281ebf76ec4a299e44b2f4342b4a6a
Autor:
Maiko Matsushita, Yoshie Ozaki, Yuka Hasegawa, Fukiko Terada, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, Tsukasa Oikawa, Koichi Matsuo, Wenlin Du, Taketo Yamada, Masashi Hozumi, Daiju Ichikawa, Yutaka Hattori
Publikováno v:
PLoS ONE, Vol 10, Iss 1, p e0116135 (2015)
Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-
Externí odkaz:
https://doaj.org/article/09bf3456f4c745db8b4addd92ca12040
Autor:
Hirokazu Shiheido, Fukiko Terada, Noriko Tabata, Ichigo Hayakawa, Nobutaka Matsumura, Hideaki Takashima, Yoko Ogawa, Wenlin Du, Taketo Yamada, Mitsuru Shoji, Takeshi Sugai, Nobuhide Doi, Shiro Iijima, Yutaka Hattori, Hiroshi Yanagawa
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e38878 (2012)
Despite the introduction of newly developed drugs such as lenalidomide and bortezomib, patients with multiple myeloma are still difficult to treat and have a poor prognosis. In order to find novel drugs that are effective for multiple myeloma, we tes
Externí odkaz:
https://doaj.org/article/39b2b178d8884a0d95e69700689dc38f
Autor:
Hirokazu Shiheido, Yuhei Naito, Hironobu Kimura, Hiroaki Genma, Hideaki Takashima, Mayuko Tokunaga, Takao Ono, Tatsuya Hirano, Wenlin Du, Taketo Yamada, Nobuhide Doi, Shiro Iijima, Yutaka Hattori, Hiroshi Yanagawa
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e44889 (2012)
We screened 46 novel anilinoquinazoline derivatives for activity to inhibit proliferation of a panel of human cancer cell lines. Among them, Q15 showed potent in vitro growth-inhibitory activity towards cancer cell lines derived from colorectal cance
Externí odkaz:
https://doaj.org/article/22190676976343cc9219470aa6ad3a5d
Autor:
Mikio Okayama, Kota Fujimori, Mariko Sato, Koichi Samata, Koki Kurita, Hiromu Sugiyama, Yutaka Suto, Genji Iwasaki, Taketo Yamada, Fumiyuki Kiuchi, Daiju Ichikawa, Maiko Matsushita, Maki Hirao, Hisako Kunieda, Kohei Yamazaki, Yutaka Hattori
Publikováno v:
Cancer Medicine. 12:9749-9759
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e824901436a9262510fda55cc621864
https://doi.org/10.1002/cam4.5691
https://doi.org/10.1002/cam4.5691